Velsera, a prominent healthcare technology company, is proud to unveil CGW Plus, an enhanced iteration of its Clinical Genomics Workspace (CGW) platform. This upgraded version introduces sophisticated workflows for variant quality assessment and clinical evidence review, tailored to expedite and streamline the analysis and reporting of genetic sequence data in clinical laboratories.
Dr. Rakesh Nagarajan, Velsera's Chief Medical Officer, emphasized the platform's commitment to enhancing the user experience for laboratory professionals. "With CGW Plus, we're setting a new benchmark in the clinical genomics field," he stated. "Our aim is to provide seamless access to precise and comprehensive data, optimizing workflow efficiency and ultimately enhancing patient care through faster and more accurate reporting."
A standout feature of CGW Plus is its expanded capabilities in clinical and biological evidence review. Utilizing automated oncogenicity evaluations sourced from COSMIC, ClinVar, and other databases, the platform facilitates efficient triaging of variants. Its intuitive graphical interface enables swift evaluation of preconfigured filter logic, streamlining the review process and eliminating the need for repetitive manual tasks.
The platform further accelerates the reporting process with automated draft interpretive text that dynamically updates based on user decisions and adheres to regional guidelines and drug label sources. CGW Plus supports comprehensive molecular results reporting, encompassing individual variants, co-occurring mutations, and key biomarkers such as Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI). Integration of non-NGS results like Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) into final reports enhances diagnostic clarity.
Adaptive learning and memory features enable users to consolidate therapeutic, prognostic, and diagnostic biomarker associations into a unified view, promoting consistency across cases within specific disease contexts. Novelty alerts highlight changes in interpreted variants, ensuring efficient review and decision-making.
CGW Plus also introduces innovative reporting capabilities with dynamic PDF rendering for accurate and efficient report finalization. Its location-aware clinical trial matching interface assists clinicians in swiftly identifying relevant investigational therapies based on variant and tumor type criteria.
Moreover, the platform offers a versatile variant table view that allows laboratory staff to efficiently review and triage variants according to assay performance characteristics and established lab protocols.
Velsera complements CGW Plus with a suite of industry-leading clinical enablement and regulatory guidance services, including validation services and medical director sign-out, reinforcing its commitment to supporting clinical laboratory workflows and precision medicine.
Velsera is dedicated to serving as a pivotal platform for discovery, evidence generation, and clinical delivery in precision medicine. By empowering clinical diagnostics and life sciences experts, Velsera enables informed decisions in therapy selection for optimal patient outcomes.
